Introduction

Dietary and biliary cholesterol are taken up by intestinal epithelial cells and transported to the endoplasmic reticulum (1). Pharmacological intervention through the inhibition of intestinal cholesterol absorption is a useful strategy for treating patients with dyslipidemia. Ezetimibe [ 1-( 4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxy propyl]-(4S)-(4-hydroxypropyl)-2-azetidinone] potently inhibits cholesterol and phytosterol uptake (2). Niemann-Pick C1-like 1 (NPC1L1) has recently been identified and has been shown to have features of a plasma membrane transporter, including a secretion signal, 13 predicted transmembrane domains, extensive N-linked glycosylation sites and a sterol-sensing domain (3) (Fig. 1). It is highly expressed on the surface of absorptive jejunal enterocytes. NPC1L1 has been shown to be a direct target of ezetimibe, and an ezetimibe-sensitive pathway plays a role in intestinal cholesterol absorption (4). These findings represent an exciting new area in the treatment of dyslipidemia. This review will address the roles of NPC1L1 and its inhibitor ezetimibe in cardiovascular disease.
Molecular Basis of Niemann-Pick C1-Like 1 (NPC1L1)
The two known complementation groups of NiemannPick disease type C (NPC), NPC1 and NPC2, result from non-allelic protein defects. NPC1 disease caused by defects in the NPC1 protein is a recessive cholesterol-storage disorder characterized by severe, progressive neurodegeneration (5) . NPC1L1 is a 145-kDa membrane protein (6) (8) (17) . Pioglitazone significantly reduces NPC1L1 mRNA and significantly increases ABCG5 and G8 mRNA compared to insulin (17) . The expression of ABCG5 and ABCG8 mRNA is lower in diabetic patients and microsomal triglyceride transfer protein (MTTP) expression is increased (18) (Fig. 2) . The enhanced NPC1L1 expression is correlated with cholesterol depletion, consistent with transcriptional regulation. (21) . Since these effects are blocked by treatment with ezetimibe, ezetimibe may reduce plasma cholesterol by inhibiting NPC1L1 function in both the intestine and liver (21) . In addition, a direct interaction between NPC1L1 and ezetimibe was shown in an in vitro binding assay (22 
NPC1L1, and may be through scavenger receptor type BI (SR-BI)
Molecular Target of Ezetimibe
Ezetimibe blocks the uptake of oxidized low-density lipoprotein (LDL) in human macrophages (19). This compound has no effect on the uptake and/or processing of acetylated LDL (Ac-LDL). In addition, it blocks the lipid-induced induction of the LXR/RXR target genes
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ezetimibe improves the insulin and plasma glucose response after intraperitoneal glucose injection, and enhances insulin signaling in cultured hepatocytes (23) .
Beneficial Effects of Ezetimibe in Humans
Monotherapy
Ezetimibe can effectively lower plasma LDL cholesterol to decrease cholesterol absorption (24) . Ezetimibe 10 mg/ day induces approximately a 20% reduction in LDL cholesterol (25) (Fig. 3) (Fig. 4) (Fig. 3) 
(25). In patients with type 2 diabetes mellitus (DM), combination therapy is usually required to optimize glucose metabolism as well as to help patients achieve aggressive tar-
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Safety of Ezetimibe in Humans
Ezetimibe/statin combination therapy was well-tolerated in 2,382 patients with primary hypercholesterolemia (37) . Moreover, the safety and tolerability profiles for the ezetimibe/simvastatin and ezetimibe monotherapy groups were similar in a randomized, double-blind, placebocontrolled trial (38) . The combination therapy of ezetimibe and statin was equally safe across specific age groups: age < 65 versus more than 65 years; age <75 versus more than 75 years (39) . Simvastatin therapy is a well-tolerated and effective therapy for children with heterozygous FH (40) 
